Vaccines (Dec 2022)

Vaccine-Acquired SARS-CoV-2 Immunity versus Infection-Acquired Immunity: A Comparison of Three COVID-19 Vaccines

  • Marie I. Samanovic,
  • Aaron L. Oom,
  • Amber R. Cornelius,
  • Sophie L. Gray-Gaillard,
  • Trishala Karmacharya,
  • Michael Tuen,
  • Jimmy P. Wilson,
  • Meron F. Tasissa,
  • Shelby Goins,
  • Ramin Sedaghat Herati,
  • Mark J. Mulligan

DOI
https://doi.org/10.3390/vaccines10122152
Journal volume & issue
Vol. 10, no. 12
p. 2152

Abstract

Read online

Around the world, rollout of COVID-19 vaccines has been used as a strategy to end COVID-19-related restrictions and the pandemic. Several COVID-19 vaccine platforms have successfully protected against severe SARS-CoV-2 infection and subsequent deaths. Here, we compared humoral and cellular immunity in response to either infection or vaccination. We examined SARS-CoV-2 spike-specific immune responses from Pfizer/BioNTech BNT162b2, Moderna mRNA-1273, Janssen Ad26.COV2.S, and SARS-CoV-2 infection approximately 4 months post-exposure or vaccination. We found that these three vaccines all generate relatively similar immune responses and elicit a stronger response than natural infection. However, antibody responses to recent viral variants are diminished across all groups. The similarity of immune responses from the three vaccines studied here is an important finding in maximizing global protection as vaccination campaigns continue.

Keywords